JP7497353B2 - Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 - Google Patents

Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 Download PDF

Info

Publication number
JP7497353B2
JP7497353B2 JP2021531817A JP2021531817A JP7497353B2 JP 7497353 B2 JP7497353 B2 JP 7497353B2 JP 2021531817 A JP2021531817 A JP 2021531817A JP 2021531817 A JP2021531817 A JP 2021531817A JP 7497353 B2 JP7497353 B2 JP 7497353B2
Authority
JP
Japan
Prior art keywords
elacestrant
subject
dose
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021531817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511497A (ja
JPWO2020118202A5 (enExample
Inventor
パテル，ヒティシャ
ビハニ，ティール
アールト，ハイク
タオ，ニアンジュン
Original Assignee
ラジウス ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラジウス ファーマシューティカルズ，インコーポレイテッド filed Critical ラジウス ファーマシューティカルズ，インコーポレイテッド
Publication of JP2022511497A publication Critical patent/JP2022511497A/ja
Publication of JPWO2020118202A5 publication Critical patent/JPWO2020118202A5/ja
Priority to JP2024086821A priority Critical patent/JP2024101017A/ja
Application granted granted Critical
Publication of JP7497353B2 publication Critical patent/JP7497353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021531817A 2018-12-06 2019-12-06 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法 Active JP7497353B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024086821A JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
US62/776,338 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024086821A Division JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Publications (3)

Publication Number Publication Date
JP2022511497A JP2022511497A (ja) 2022-01-31
JPWO2020118202A5 JPWO2020118202A5 (enExample) 2022-12-19
JP7497353B2 true JP7497353B2 (ja) 2024-06-10

Family

ID=69158304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531817A Active JP7497353B2 (ja) 2018-12-06 2019-12-06 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
JP2024086821A Pending JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024086821A Pending JP2024101017A (ja) 2018-12-06 2024-05-29 Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法

Country Status (17)

Country Link
US (2) US20220016052A1 (enExample)
EP (1) EP3890835A1 (enExample)
JP (2) JP7497353B2 (enExample)
KR (1) KR20210100135A (enExample)
AU (1) AU2019392908B2 (enExample)
BR (1) BR112021010141A2 (enExample)
CA (1) CA3121918A1 (enExample)
EA (1) EA202191256A1 (enExample)
IL (1) IL283655A (enExample)
JO (1) JOP20210138A1 (enExample)
MA (1) MA54393A (enExample)
MX (1) MX2021006412A (enExample)
MY (1) MY208702A (enExample)
PH (1) PH12021551327A1 (enExample)
SG (1) SG11202105915UA (enExample)
UA (1) UA129588C2 (enExample)
WO (1) WO2020118202A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514549A (ja) 2015-04-29 2018-06-07 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3834824T3 (fi) * 2014-03-28 2025-12-05 Univ Duke Estrogeenireseptoripositiivisen rintasyövän hoito selektiivisellä estrogeenireseptorin modulaattorilla

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018514549A (ja) 2015-04-29 2018-06-07 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2018514593A (ja) 2015-04-29 2018-06-07 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
JP2018518529A (ja) 2015-04-29 2018-07-12 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Clinical Cancer Research，2017年，Vol.23, No.6，p.4793-4804

Also Published As

Publication number Publication date
CA3121918A1 (en) 2020-06-11
EA202191256A1 (ru) 2021-10-06
KR20210100135A (ko) 2021-08-13
MA54393A (fr) 2021-10-13
PH12021551327A1 (en) 2022-04-25
IL283655A (en) 2021-07-29
JP2022511497A (ja) 2022-01-31
JP2024101017A (ja) 2024-07-26
WO2020118202A1 (en) 2020-06-11
EP3890835A1 (en) 2021-10-13
BR112021010141A2 (pt) 2021-08-24
AU2019392908A1 (en) 2021-06-10
US20250241875A1 (en) 2025-07-31
MY208702A (en) 2025-05-25
UA129588C2 (uk) 2025-06-11
SG11202105915UA (en) 2021-07-29
AU2019392908B2 (en) 2025-02-20
US20220016052A1 (en) 2022-01-20
MX2021006412A (es) 2021-07-21
JOP20210138A1 (ar) 2023-01-30

Similar Documents

Publication Publication Date Title
JP7516472B2 (ja) 癌を治療するための方法
JP7504097B2 (ja) Ｃｄｋ４／６阻害剤に耐性の癌を治療するための方法
JP2025094216A (ja) 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
JP7497353B2 (ja) Ｅｓｒ１変異を含むモデルにおいて癌を治療するための方法
RU2822195C2 (ru) Способы лечения рака на моделях, имеющих мутации esr1
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака
EA046925B1 (ru) Способы лечения рака на моделях, имеющих мутации esr1
EA047283B1 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240529

R150 Certificate of patent or registration of utility model

Ref document number: 7497353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150